Patient and physician perspectives on disease burden in chronic spontaneous urticaria: A real-world US survey.

Background: Chronic spontaneous urticaria (CSU) is frequently associated with severe disease-related symptoms that negatively affect quality of life, but patients and physicians may differ in their opinion on CSU burden.

Objective: To describe the clinical and humanistic burden associated with CSU and level of agreement between patient and physician perceptions of disease burden and treatment satisfaction.

Methods: This cross-sectional, survey-based study of US physicians and their adult patients with CSU included data collected in the Adelphi CSU Disease Specific Programme from 2020 to 2021.

Do regional geography and race influence management of chronic spontaneous urticaria?

Chronic spontaneous urticaria is defined as migratory evanescent pruritic blanching wheals that occur with variable frequency for 6 weeks or more, with or without accompanying angioedema. This condition affects approximately 0.1% to 1.

A Severe Case of Minocycline-induced Hyperpigmentation of the Lower Extremities.

Drug reactions are a common cause of cutaneous eruptions. The authors present a case of shin hyperpigmentation resulting from long-term minocycline treatment. This case illustrates a severe example of minocycline-induced pigmentation and reminds clinicians who prescribe this commonly used antibiotic to remain vigilant of this rare adverse reaction.

Biologics for the primary care physician: Review and treatment of psoriasis.

Psoriasis is a chronic inflammatory disease that affects approximately 7.5 million people in the United States. The disease results in significant suffering, morbidity, and economic impact.

Treating psoriasis with adalimumab.

Psoriasis is a common, chronic, inflammatory skin disease that can have a significant impact on the quality of life of those who are afflicted. Recent advances in the understanding of the pathophysiology of psoriasis have led to the development of new, genetically engineered, targeted therapies for this disease. Among the most successful strategies for treatment has been the use of biologic immunotherapies targeting tumor necrosis factor alpha (TNF).

From laboratory to clinic: rationale for biologic therapy.

Traditional systemic therapy for psoriasis is limited by either lack of efficacy or the long-term side effect profile of the medications used. Newer information about the pathophysiology of the disease has led to new perspectives on developing novel techniques for attacking psoriasis. This article discusses the pathogenesis of psoriasis, looks at the immunologic factors that contribute to forming a psoriatic plaque, reviews how novel biologic therapies are made, and explores how biologics can target each of these specific parts of the immunologic cascade.

The immunology of psoriasis and biologic immunotherapy.

In this review, we will discuss the immunological basis for psoriasis with special emphasis on the role of effector T cells. With the understanding of this immunologic process, we will present a model for the development of targeted immune response modifiers, termed biologic immunotherapies, and their potential role for the benefit of patients with psoriasis.